Andrew joined the CDCN as Associate Director of Commercial Partnerships in 2014.  Previously, Andrew worked as a healthcare focused venture capitalist with Fidelity Biosciences.  At Fidelity, he invested in early stage biotech, medtech, healthcare IT and healthcare services startups, including several rare disease biotech companies. Prior to Fidelity, Andrew was a strategy consultant with Leerink Partners, a boutique healthcare focused investment bank and consulting firm.  While there, he advised pharmaceutical and biotech clients on their growth strategies.

Andrew is currently an MBA student in Wharton's Health Care Management program, and holds a BA in Biological Basis of Behavior from the University of Pennsylvania.  While at Penn, he conducted research in the neuroscience department and also worked for the Penn Resiliency Project, an international NIMH-funded study.